Newsbenzinga
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push
· Published
Article summary
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
An excerpt from the original article.
Comments —
Loading comments…